Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS)

BACKGROUND: Lebrikizumab is a monoclonal antibody that modulates activity of interleukin‐13. The Phase 3 ACOUSTICS study assessed lebrikizumab efficacy and safety in adolescents with uncontrolled asthma despite standard‐of‐care treatment. METHODS: Adolescents (aged 12–17 years) with uncontrolled ast...

Descripción completa

Detalles Bibliográficos
Autores principales: Szefler, Stanley J., Roberts, Graham, Rubin, Adalberto S., Zielen, Stefan, Kuna, Piotr, Alpan, Oral, Anzures‐Cabrera, Judith, Chen, Qiang, Holweg, Cécile T. J., Kaminski, Janusz, Putnam, Wendy S., Matthews, John G., Kamath, Nikhil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281483/
https://www.ncbi.nlm.nih.gov/pubmed/35846226
http://dx.doi.org/10.1002/clt2.12176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281483/
https://www.ncbi.nlm.nih.gov/pubmed/35846226
http://dx.doi.org/10.1002/clt2.12176

Ejemplares similares